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Summary
Difficulties in diagnosis of inflammatory bowel disease (IBD) motivate the search for new dia-
gnostic tools, including laboratory tests. The aim of this study was to evaluate concentrations 
of the neutrophil (NEU) proteins leukocyte elastase (HLE-α1AT), lactoferrin and calprotectin 
as potential biomarkers used in the diagnosis and assessment of clinical activity of Crohn’s 
disease (CD) and ulcerative colitis (UC).
The study included 27 patients with CD, 33 patients with UC and 20 healthy controls. Plasma 
concentrations of calprotectin, lactoferrin and HLE-α1AT were measured using ELISA. 
In patients with CD higher concentrations of HLE-α1AT (64.3±43.1 vs. 30.1±7.7 ng/l, P<0.001), 
calprotectin (151.6±97.8 vs. 69.9±22.1 ng/l, P<0.001) and lactoferrin (243.2±102.0 vs. 129.7±32.7 
ng/l, P<0.001) than in the control group were found. In patients with UC higher plasma con-
centrations of HLE-α1AT (62.0±30.9 vs. 30.1±7.7 ng/l, P<0.001), calprotectin (149.6±72.3 vs. 
69.9±22.1 ng/l, P<0.001) and lactoferrin (242.6±107.5 vs 129.7±32.7 ng/l, P<0.001) than in the 
control group were found. HLE-α1AT/NEU and lactoferrin/NEU ratios in patients with UC were 
significantly higher compared with patients with CD. Calprotectin (P=0.010) and lactoferrin 
(P=0.023) levels were higher in patients with the active compared with inactive phase of CD. 
The diagnostic characteristics of plasma granulocyte protein concentrations indicate the 
usefulness of these tests in the diagnosis of IBD. Higher HLE-α1AT and lactoferrin/NEU ratios 
in patients with UC than with CD may suggest the usefulness of these ratios in differential 
diagnostics. Plasma calprotectin and lactoferrin levels may be useful in CD activity assessment. 
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IntroductIon
The prevalence of inflammatory bowel disease (IBD) has 
increased in recent years and continues to grow [1,17,18]. 
In Poland, according to data from the National Register, 
in July 2015 there were 6130 people with Crohn’s disease 
(CD) [20]. No data on the number of patients with ulcera-
tive colitis (UC) in Poland are available. The pathogene-
sis of IBD is not fully elucidated; genetic predisposition, 
immunological and intestinal microbiota changes are 
taken into consideration. IBD requires long-term treat-
ment to achieve remission and to prevent relapses and 
cancer, and in both CD and UC the prognosis is unfavoura-
ble. However, in many patients only a transient remission 
can be achieved. These diseases significantly reduce the 
quality of the patient’s life, limiting the ability to perform 
many daily and professional activities, often leading to 
chronic disability, not only physical but also psychosocial 
[3,21]. Therefore, in order to improve treatment methods 
new diagnostic tools are developed to ensure early dia-
gnosis, risk stratification and treatment monitoring. 
New laboratory tests that can be easily available diagno-
stic tools assessing IBD activity and clinical severity, and 
monitoring the treatment seem to be necessary [16,21].
Neutrophils (NEU) are involved in the innate immune 
response and have a large arsenal of antibacterial 
mechanisms including the ability to phagocytose and 
produce NET (neutrophil extracellular traps). As cells 
participating in the inflammatory response, neutrophils 
are involved in the pathogenesis of IBD, as evidenced 
by the results of experimental and histopathology stu-
dies revealing their presence in the inflamed intestinal 
wall [15]. In light of the other data, neutrophils’ invo-
lvement in the pathogenesis of IBD should be conside-
red in the context of their dysfunction, which is one of 
the immune system abnormalities observed in this dise-
ase. Multiple proteins released from cell granules inc-
luding elastase, calprotectin and lactoferrin, which are 
easily measurable in faeces and plasma, can reflect neu-
trophils’ activation. These measurements may be use-
ful as an alternative or tests added to the routinely used 
inflammatory markers in the diagnosis of IBD [2,23,25].
The aim of this study was to evaluate the usefulness of 
measurements of selected neutrophil protein concentra-
tions in the diagnosis of IBD, differential diagnostics of 
CD and UC, and in assessing the severity of these dise-
ases.
Methods
The study included a group of 60 patients with IBD (33 
with UC and 27 with CD, aged from 18 to 75 years) and 
20 healthy subjects in the control group. The patients 
were hospitalized in the Department of Gastroentero-
logy, Hepatology and Infectious Diseases of the Univer-
sity Hospital, Krakow, Poland in the years 2010 to 2013. 
The diagnosis of CD and UC was based on the clinical 
assessment including patient’s history, physical exami-
nation and endoscopy with the histological evaluation 
of intestinal mucosal biopsy specimens as well as results 
of imaging studies. The criteria for exclusion from the 
study were coexisting malignancy, endocrine disorders, 
diabetes, obesity, ischemic heart disease and systemic 
diseases. The control group consisted of 20 healthy sub-
jects aged 20 to 61 years. The UC patients were divided 
into the active (23 patients) and inactive (10 patients) 
phase of the disease subgroups according to the Tru-
elove-Witts index based on the number of bowel move-
ments per day and systemic abnormalities [24]. The UC 
patients with mild disease and remission in the Tru-
elove-Witts scale were assigned to the inactive subgroup 
whereas the patients classified as having moderate or 
severe disease were assigned to the active subgroup. The 
CD patients, according to the Crohn’s disease activity 
index (CDAI), were divided into active for CDAI>150 (16 
patients) and for CDAI<150 inactive (11 patients) phase 
of disease subgroups [4].
The Bioethical Committee of the Jagiellonian University 
in Krakow, Poland approved the study and all patients 
expressed their consent to participate in the study. 
This study was funded by a grant from the Natio-
nal Science Centre Prelude Grant No. Dec-2011/01/N/
NZ5/02757. Publication was supported by the Faculty 
of Medicine of Jagiellonian University Medical College 
(Leading National Research Centre 2012–2017).
Venous blood was collected using S-Monovette tubes 
(Sarstedt, Germany). Plasma was separated and aliqu-
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significance level p<0.05 was applied. Based on the ROC 
(receiver operating characteristics) curves analysis, rele-
vant cut-off values were selected, and diagnostic accu-
racy, sensitivity, specificity, positive predictive values, 
negative predictive values, and likelihood ratios for posi-
tive and negative results were calculated. Furthermore, 
ratios of granulocyte protein concentrations to leuko-
cyte (WBC) and neutrophil (NEU) counts were evaluated 
as parameters reflecting neutrophil activity.
results
Table 1 shows a comparison of the analyzed results in 
patients with CD, CU and the control group. CRP, pla-
sma lactoferrin, lactoferrin/WBC ratio, calprotectin 
concentration, calprotectin/WBC ratio, HLE-α1AT level, 
and HLE-α1AT/WBC ratio were significantly higher in 
patients with CD. The median concentrations of lacto-
ferrin, calprotectin, HLE-α1AT, and neutrophil proteins/
oted into polypropylene tubes for deep-freezing, and 
stored at – 70°C until assayed. C-reactive protein (CRP) 
was measured using immunonephelometric assay on the 
Nephelometer II Analyzer (Siemens Healthcare Diagno-
stics). The rest of the selected parameters were determi-
ned using the ELISA method, using the appropriate kits: 
leukocyte elastase – alpha-1 antitrypsin complex (HLE-
α1AT) (PMN Elastase ELISA, BioVendor, Czech Republic), 
plasma calprotectin (Hycult Biotechnology Company, 
USA), plasma lactoferrin (Hycult Biotechnology Com-
pany, USA).
Normality of distribution of the results was assessed 
using the Kolmogorov-Smirnov test. Normally distri-
buted results were presented as means and standard 
deviations, and means were compared using the t test. 
Nonparametrically distributed results were presented 
as medians and inter-quartile differences, and medians 
were compared using the Mann-Witney U-test. The 
Table 1. Comparison of the test results and calculated ratios in control group and patients with inflammatory bowel disease
Studied Groups P
Control group 
(n=20)
Crohn’s disease 
(n=27) 
Ulcerative colitis 
(n=33)
Control group 
vs
 Crohns 
disease
Control group 
vs
Ulcerative 
Colitis
Crohns disease 
vs
CU
CRP [mg/l]
1.1
(0.51-2.14)
6.4
(0.5-20.5)
2.3
(1.1-19.6)
0.028 0.012 NS
WBC 103/uL]
5.7 
(4.9-6.6)
8.3
(6.2-10.0)
6.4
(5.3-8.9)
0.003 NS NS
NEU [103/uL]
3.02
(2.35-3.75)
6.25
(4.14-7.44)
4.00
(3.20-5.58)
>0.001 0.015 0.023
Lactoferrin [ng/mL] 129.7±32.7 243±102 243±108 >0.001 >0.001 NS
Lactoferrin
WBC
21.9 
(17.1-25.2)
32.9
(24.0-35.4)
29.9
(24.6-40.7)
0.008 0.003 NS
Lactoferrin
NEU
40.0
(32.2-59.2)
43.5
(31.7-52.6)
48.6
(42.5-70.3)
NS 0.049 0.033
Calprotectin [ng/mL] 69.9±22.1 151.6±97.8 149.6±72.3 >0.001 >0.001 NS
Calprotectin  WBC
12.7
(8.4-17.4
20.0
(13.7-25.7)
15.8
(12.9-28.8)
0.007 0.010 NS
Calprotectin
NEU
19.7
(16.1-33.2)
23.4
(16.8-42.6)
23.2
(18.7-51.6)
NS NS NS
HLE-α1AT [ng/mL] 30.1±7.7 64.3±43.1 62.0±30.9 0.001 >0.001 NS
HLE-α1AT  WBC
5.3
(4.2-6.7)
6.7
(5.8-9.2)
8.4
(6.5-9.9)
0.006 >0.001 NS
HLE-α1AT  NEU
9.9
(7.4-13.2)
10.3
(7.2-13.4)
12.8
(10.9-15.9)
NS 0.012 0.049
Results are presented in the form of mean±standard deviation and median (first quartile-third quartile). Abbreviations: CRP - C-reactive protein, WBC - White blood 
Cells, NEU - Neutrophils  HLE-α1AT  - leukocytes elastase - alfa 1 antytripsine, P – level level of statistical ignificance,NS - not significant of statistical significance, 
NS - not significant
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nulocyte proteins/NEU ratios AUCs were less than 0.6. 
Table 3 shows diagnostic characteristics of the tests 
evaluated in CD patients and controls. High accuracy, 
sensitivity, specificity, predictive values, and likelihood 
ratios (LR+) were found for lactoferrin, calprotectin and 
HLE-α1AT. Neutrophil count was characterized by high 
accuracy, sensitivity and negative predictive value whe-
reas for granulocyte proteins/NEU ratios low accuracy 
(approximately 50%), high sensitivity and negative pre-
dictive value were found. High positive predictive value 
was found only for lactoferrin/WBC ratio and calprotec-
tin/WBC ratio. 
Figure 2 presents the ROC curves for the evaluated tests 
in patients with UC and controls. The largest areas under 
the curves were found for neutrophil count (0.708), pla-
sma calprotectin (0.824), lactoferrin (0.855), and HLE-
α1AT (0.900). For granulocyte proteins/WBC ratios 
between 0.7 and 0.8 were found, while for granulocyte 
proteins/NEU ratios AUCs below 0.7 were found. 
In Table 3 diagnostic characteristics of the tests eva-
luated in patients with UC and the control group are 
WBC ratios were twice as high in patients with CD as in 
the control group. The median lactoferrin/NEU ratio, 
calprotectin/NEU ratio and HLE-α1AT/NEU ratio did not 
differ significantly between these two groups.
CRP, plasma lactoferrin, lactoferrin/WBC ratio, lactofer-
rin/NEU ratio, plasma calprotectin, calprotectin/WBC 
ratio, and HLE-α1AT level were significantly higher in 
patients with UC compared with the control group. The 
medians of lactoferrin, calprotectin and HLE-α1AT levels 
were in patients with UC twice as high as in the control 
group. No significant differences in calprotectin/NEU 
ratio between patients with UC and controls were found. 
Only neutrophil count, lactoferrin/NEU ratio and HLE-
α1AT/NEU ratio were significantly higher in patients 
with UC than in CD patients. 
Figure 1 shows the ROC curves analysis for tests evalu-
ated in patients with CD and controls. Areas under the 
ROC curves (AUCs) above 0.8 were found for neutrophil 
count (0.850), plasma calprotectin (0.854), lactoferrin 
(0.872) and HLE-α1AT (0.900). For granulocyte proteins/
WBC ratios AUCs below 0.8 were found, and for the gra-
Table 2. Diagnostic characteristics of the evaluated tests and ratios in the diagnosis of Crohn’s disease
Cut-off 
value
Accurancy
(%)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
%
LR+
CRP [mg/L] 4.7 48.5 80.0 60.4 70.0 48.5 2.31
WBC [103/uL] 6.5 73.3 72.0 75.0 78.3 68.2 2.88
NEU [103/uL] 3.8 80.0 85.0 75.0 77.3 83.3 3.40
Lactoferrin [ng/mL] 161.7 87.2 85.2 90.0 92.0 81.8 8.52
Lactoferrin
WBC
26.6 73.3 68.0 80.0 81.0 66.7 3.40
Lactoferrin
NEU
23.9 55.0 100.0 10.0 52.6 100.0 1.11
Calprotectin [ng/mL] 99.1 83.0 77.8 90.0 91.3 75.0 7.78
Calprotectin WBC 18.5 71.1 56.0 90.0 87.5 62.1 5.60
Calprotectin NEU 8.2 55.0 100.0 10.0 52.6 100.0 1.11
HLE-α1AT [ng/mL] 40.1 85.1 81.5 90.0 91.7 78.3 8.15
HLE-α1AT
WBC
5.2 71.1 88.0 50.0 68.8 76.9 1.76
HLE-α1AT 
NEU
5.1 52.5 100.0 25.0 51.3 100.0 1.05
Abbreviations:  CRP - C-reactive protein,  WBC - White blood Cells, NEU - Neutrophils , HLE-α1AT  - leukocytes elastase - alfa 1 antytripsine, PPV- positive predictive 
value, NPV- negative predictive value, LR+ - likelyhood ratio for positive result
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Fig. 1. ROC curves analysis for the test results and calculated ratios in patients with Crohn’s disease and control group. (Abbreviations: ROC – receiver operating 
characteristics NEU – neutrophils, WBC – white blood cells)
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Fig. 2. ROC curves analysis for the test results and calculated ratios in patients with ulcerative colitis and control group. (Abbreviations: ROC – receiver operating 
characteristics, NEU – neutrophils, WBC – white blood cells)
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establish based on the clinical, imaging and histological 
evaluation [27]. These difficulties motivate the search 
for new diagnostic tools including laboratory tests, 
which could be used to diagnose, assess the severity and 
prognosis, and to monitor the treatment of IBD.
It was observed that CRP was characterized by a low dia-
gnostic sensitivity and specificity, and low predictive 
values of the results and the likelihood ratio for a posi-
tive result, which indicates little use of this test in the 
diagnosis of CD and UC (Tables 3 and 4). Elevated CRP 
levels seem to be a good indicator of clinical activity 
of CD and UC (Table 5). Similar findings were observed 
by Lehrke et al., who found a higher concentration of 
CRP in patients with active CD and UC compared to the 
remission [14].
Based on growing evidence for the involvement of neu-
trophils in the pathogenesis of IBD we evaluated plasma 
granulocyte protein levels in patients with CD and UC. 
We found significantly higher concentrations of the stu-
died granulocyte proteins in patients with CD and UC 
compared with the control group (Table 1). The largest 
areas under the ROC curves were found for HLE-α1AT in 
both diseases (Figures 1 and 2). In the diagnosis of CD, 
taking the cut-off value of 40 ng/mL HLE-α1AT had dia-
gnostic sensitivity, specificity and positive predictive 
value above 80%, and negative predictive value close to 
80% (Table 2). Similar diagnostic characteristics for HLE-
shown. High accuracy, sensitivity, specificity, and predic-
tive values for lactoferrin, calprotectin, and HLE-α1AT 
were found. Calprotectin had the highest LR+.
In Table 5 the results of performed tests and calculated 
ratios in patients with active and inactive CD are com-
pared. In patients with active CD significantly higher 
levels of lactoferrin and calprotectin were found. The 
mean lactoferrin and calprotectin concentrations were 
almost twice as high as in patients in inactive CD. Dif-
ferences between calprotectin and lactoferrin/WBC and 
NEU ratios were not significant. The concentration of 
lactoferrin and calprotectin had little effect on the odds 
of active disease (increase by 1.4% and 3.5%, respecti-
vely) (Table 5). Other tests and calculated ratios were not 
associated with clinical activity of CD.
The same comparisons between patients with exacerba-
tion and remission of UC were also made (Table 4). In 
patients with active UC significantly higher leukocyte 
and neutrophil counts were found. Changes in measu-
red protein concentrations and calculated ratios did not 
significantly increase the odds of active UC (Table 5).
dIscussIon
Recent data indicate that the diagnosis of IBD is esta-
blished up to three years after onset of symptoms [19]. 
Moreover, the diagnosis in 5-15% of cases is difficult to 
Table 3. Diagnostic characteristics of the evaluated tests and ratios in the diagnosis of ulcerative colitis
   
Cut-off 
value
Accurancy
(%)
Sensitivity
(%)
Specificity
(%)
PPV
%
NPV
%
LR+
CRP [mg/L] 3.0 48.5 80.0 60.4 80.0 48.5 2.42
WBC [103/uL] 5.1 81.3 35.0 63.5 66.7 53.8 1.25
NEU [103/uL] 3.0 79.3 45.0 65.3 67.6 60.0 1.44
Lactoferrin [ng/mL] 170.4 78.8 90.0 83.0 92.9 72.0 7.88
Lactoferrin
WBC
26.1 75.0 80.0 76.9 85.7 66.7 3.75
Lactoferrin
NEU
42.5 75.9 60.0 69.4 73.3 63.2 1.90
Calprotectin [ng/mL] 108.3 69.7 95.0 79.2 95.8 65.5 13.94
Calprotectin WBC 11.5 90.6 50.0 75.0 74.4 76.9 1.81
Calprotectin NEU 18.2 82.8 45.0 67.3 68.6 64.3 1.50
HLE-α1AT [ng/mL] 35.3 84.8 80.0 83.0 87.5 76.2 4.24
HLE-α1AT
WBC
5.8 81.3 65.0 75.0 78.8 68.4 2.32
HLE-α1AT 
NEU
10.5 79.3 65.0 73.5 76.7 68.4 2.27
Abbreviations: CRP - C-reactive protein, WBC - White blood Cells , NEU - Neutrophils, HLE-α1AT  - leukocytes elastase - alfa 1 antytripsine, PPV- positive predictive 
value, NPV- negative predictive value, LR+ - likelyhood ratio for positive result
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the disease and patients in remission (Table 4). In patients 
with active UC significantly higher leukocyte and neutro-
phil counts compared with patients in inactive UC were 
found (Table 5). Altogether, these results indicate poor 
suitability of plasma granulocyte protein measurements 
for the assessment of UC clinical activity. It should be 
noted, however, that the evaluation of these relationships 
was influenced by the small number of patients in remis-
sion of both CD and UC. 
Leucocyte elastase is involved in the pathogenesis of IBD, 
and the relationship between IBD activity and the con-
centration of this enzyme in both plasma and faeces has 
recently been reported [8,22]. As shown in Tables 1 and 2, 
high plasma concentration of the HLE-α1AT complex in 
patients with CD and UC may reflect increased neutrophil 
activity. This seems to be confirmed by the significantly 
increased neutrophil count in patients with IBD. Gouni-
-Berthold et al. reported increased plasma HLE-α1AT con-
centrations in patients with UC, which correlated with 
α1AT using the cut-off value of 35.3 ng/mL were found 
in the diagnosis of UC (Table 3). Moreover, large areas 
under the ROC curves in the diagnosis of CD (Figure 1) 
and UC (Figure 2) for lactoferrin and calprotectin were 
found. Diagnostic sensitivity, specificity and predictive 
values of these tests were close to 80% in the diagnosis 
of both UC and CD (Tables 2 and 3). Diagnostic charac-
teristics of the evaluated granulocyte proteins indicate 
that measurement of plasma HLE-α1AT, lactoferrin and 
calprotectin may be useful in the diagnosis of IBD.
We also evaluated the relationship of granulocyte pro-
tein concentrations with the activity of CD and UC (Table 
4). In patients in the active phase of CD higher lactofer-
rin and calprotectin levels than in patients in remission 
were found (Table 4). Logistic regression analysis showed 
that elevated lactoferrin and calprotectin concentrations 
significantly increase the odds of CD exacerbation (Table 
5). In the UC group all granulocyte protein levels did not 
significantly differ between patients in the active phase of 
Table 4. Comparison of the test results and calculated ratios in patients with active and inactive Crohn’s disease and ulcerative colitis 
Crohn’s disease Ulceratibe colitis
Inactive
CDAI: 108±30
N=11
Active
CDAI: 292±130
N=16
P
Inactive
N=10
Active
N=23
P
CRP [mg/L]
1.60
(0.13-6.41)
16.41
(1.73-24.04)
0.0239
0.87
(0.49-1.87)
12.70
(1.37-26.19)
0.0245
WBC [103/uL]
7.6
(5.2-9.5)
8.8
(6.5-10.0)
NS
5.3
(4.6-6.4)
7.2
(5.8-9.1)
0.029
NEU [103/uL]
5.1
(3.8-7.0)
6.5
(4.7-7.6)
NS
3.3
(2.6-3.5)
4.2
(3.5-5.9)
0.025
Lactoferrin [ng/mL] 186.3±45.2 276.7±112.0 0.023 199.8±72.0 258.6±115.3 NS
Lactoferrin
WBC
24.0
(17.2-35.3)
33.2
(28.7-38.8)
NS
29.9
(23.2-43.5)
30.0
(26.1-37.4)
NS
Lactoferrin
NEU
32.5
(24.9-47.3)
44.2
(41.0-54.3)
NS
57.9
(40.6-81.2)
47.9
(42.5-65.0)
NS
Calprotectin [ng/mL] 90.6±42.0 187.5±104.2 0.010 113.2±72.8 163.3±68.6 NS
Calprotectin WBC
13.8
(9.9-21.4)
21.9
(15.5-31.3)
NS
13.0
(11.9-17.0)
18.6
(13.5-30.7)
NS
Calprotectin NEU
17.7
(14.3-24.8)
25.9
(19.8-50.7)
NS
21.9
(20.5-43.1)
35.2
(18.3-51.6)
NS
HLE-α1AT [ng/mL] 50.8±12.9 72.2±53.5 NS 47.0±21.6 67.6±32.3 NS
HLE-α1AT
WBC
6.9 (932
6.7
(5.5-9.2)
NS
8.3
(7.0-9.2)
8.9
(6.4-10.1)
NS
HLE-α1AT 
NEU
 
10.6
(5.8-9.1)
9.3
(6.8-16.9)
NS
13.2
(11.5-15.2)
12.8
(10.1-16.6)
NS
Results are presented in the form of mean±standard deviation and median (first quartile-third quartile). Abbreviations: CRP - C-reactive protein, WBC - White blood 
Cells, NEU - Neutrophils, HLE-α1AT  - leukocytes elastase - alfa 1 antytripsine, P – level of statistical significance, NS - not significant
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trophils in the pathogenesis of IBD and diagnostic capa-
bilities of calprotectin is the study by Foell et al., who 
evaluated the release of calprotectin in the gastrointe-
stinal tract of patients with CD, UC, irritable bowel syn-
drome (IBS) and in the control group [6]. They observed 
higher release of calprotectin in the inflamed tissue, but 
found no differences between the release of calprotectin 
in the active and inactive CD.
In 2008 qualitative point-of-care tests detecting calpro-
tectin and lactoferrin in faeces were introduced for pre-
dicting exacerbations of IBD, differentiating IBD from 
functional disorders and to reduce the need for invasive 
diagnostic procedures [12]. Langhorst et al. measured 
calprotectin, lactoferrin and leukocytes in faeces and 
found that calprotectin and lactoferrin concentrations 
were significantly higher in patients with IBD than in 
the group with IBS and healthy controls [12]. As eviden-
ced in our results and published data, measurements of 
calprotectin and lactoferrin both in plasma and faeces 
may be useful in the diagnosis of IBD and its differentia-
tion from IBS, and assessment of CD activity, which can 
be helpful in therapeutic decisions making.
disease activity [8]. Diagnostic characteristics of HLE-
α1AT similar to those obtained in our study were reported 
by Kuno et al., who found that this enzyme measured in 
plasma is a useful indicator of IBD activity, better identify-
ing patients in remission than ESR and CRP [11]. We found 
that HLE-α1AT levels in plasma of patients with the active 
disease were higher than in patients with inactive dise-
ase, but the difference was not statistically significant. 
Altogether, our results confirm the usefulness of plasma 
HLE-α1AT in the diagnosis of IBD, but did not confirm its 
relationship with clinical activity of both CD and UC. As 
mentioned above, the limitation of the last analysis was 
the small number of patients in remission.
Determination of calprotectin and lactoferrin in faeces 
and plasma has been the subject of numerous studies. 
Leach et al. found that plasma calprotectin levels, both 
in patients with UC and CD, were higher than in the 
control group [20]. In this study calprotectin had high 
diagnostic sensitivity and specificity (91% and 71%, 
respectively) in the diagnosis of IBD [13]. Similar diagno-
stic characteristics for calprotectin were obtained in our 
study. Another confirmation of the involvement of neu-
Table 5. Relationship between the test results and calculated ratios and clinical activity of Crohn’s disease and ulcerative colitis – logistic regression analysis
  Crohn’s disease Ulcerative Colitis
Odds ratio
(95% confidence interval)
P
Odds ratio
(95% confidence nterval)
P
CRP [mg/L]
1.148
(1.012-1.303)
0.033
1.011
(1.002-1.218)
0.049
WBC [103/uL]
1.123
(0.777-1.622)
NS
1.560
(0.925-2.632)
NS
NEU [103/uL]
1.190
(0.729-1.943)
NS
1.970
(0.828-4.690)
NS
Lactoferrin [ng/mL]
1.014
(1.001-1.028)
0.045
1.007
(0.997-1.017)
NS
Lactoferrin
WBC
1.103
(0.987-1.232)
NS
0.995
(0.951-1.042)
NS
Lactoferrin
NEU
1.077
(0.977-1.187)
NS
0.994
(0.968-1.021)
NS
Calprotectin [ng/mL]
1.035
(1.005-1.066)
0.022
1.011
(0.998-1.024)
NS
Calprotectin WBC
1.122
(0.992-1.270)
NS
1.010
(0.940-1.085)
NS
Calprotectin NEU
1.065
(0.974-1.165)
NS
1.004
(0.962-1.048)
NS
HLE-α1AT [ng/mL]
1.018
(0.987-1.049)
NS
1.035
(0.993-1.079)
NS
HLE-α1AT
WBC
1.057
(0.851-1.314)
NS
1.035
(0.837-1.279)
NS
HLE-α1AT 
NEU
1.053
(0.886-1.251)
NS
1.035
(0.837-1.279)
NS
Results are presented in the form of mean±standard deviation and median (first quartile-third quartile) Abbreviations: CRP - C-reactive protein, WBC - White blood 
Cells, NEU - Neutrophils, HLE-α1AT  - leukocytes elastase - alfa 1 antytripsine, P – level of statistical significance, NS - not significant
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duction compared to cells from healthy subjects [7]. It 
was also observed that the migration of neutrophils in 
skin and injured bowel in patients with CD is lower than 
normal. Nonetheless, our results indicate increased neu-
trophil count and activity in IBD rather than their dys-
function.
No differences in neutrophil count and calculated ratios 
between patients with active CD and UC, and patients 
in remission were observed (Table 4). The parameters of 
diagnostic characteristics of the studied tests decreased 
in the order: concentrations of granulocyte proteins – 
proteins/WBC ratio – protein/NEU ratio (Tables 2 and 
3, Figures 1 and 2). Moreover, the AUCs for granulocyte 
proteins/NEU ratios were small and diagnostic accuracy 
of about 50% in the diagnosis of CD was found (Table 2) 
while higher diagnostic accuracy (about 70-80%) was 
observed in the UC diagnosis (Table 3). Altogether, dia-
gnostic characteristics of neutrophil count was less 
favourable than that of HLE-α1AT, calprotectin and lac-
toferrin, which suggests that granulocyte proteins are 
better candidate markers in the diagnosis of IBD than 
neutrophil count or ratios calculated in our study. 
In summary, we found that plasma HLE-α1AT, calpro-
tectin and lactoferrin levels were significantly higher in 
patients with IBD than in the control group. Diagnostic 
characteristics of plasma granulocyte protein concen-
trations indicate the usefulness of these tests in the dia-
gnosis of IBD. Significantly higher HLE-α1AT/NEU ratio 
and lactoferrin/NEU ratio in patients with UC than with 
CD suggest the potential role of these ratios in diffe-
rential diagnostics. Plasma calprotectin and lactoferrin 
levels are higher in patients with active disease than in 
remission of CD.
The main limitation of our study was the small number 
of patients in the studied groups and the lack of a com-
parison of plasma levels of granulocyte protein concen-
tration to concentration in faeces. For this reason our 
results should be considered as preliminary, and they 
require confirmation in further studies.
One of the aims of this study was to evaluate leukocyte 
and neutrophil counts and the ratios of granulocyte pro-
tein levels to WBC and NEU counts in patients with IBD. 
Significantly higher leukocyte and neutrophil counts in 
patients with CD compared with the control group but 
comparable granulocyte proteins/WBC and granulo-
cyte proteins/NEU ratios were found (Table 1). Excep-
tions were lactoferrin/WBC ratio and lactoferrin/NEU 
ratio, which were significantly higher in patients with 
CD. Although WBC count did not differentiate patients 
with UC and the control group, a significantly higher 
neutrophil count was found in UC patients (Table 1). 
Moreover, in patients with UC plasma HLE-α1AT, lacto-
ferrin and calprotectin/WBC ratios, and HLE-α1AT and 
lactoferrin/NEU ratios were significantly higher than in 
the control group (Table 1). HLE-α1AT and lactoferrin/
NEU ratios were in patients with UC significantly higher 
than in patients with CD (Table 1). From Figures 1 and 2 
it is clear that lactoferrin, calprotectin and plasma HLE-
α1AT are directly associated with NEU and the AUCs of 
lactoferrin/NEU, calprotectin/NEU and elastase/NEU 
close to 0.5 in CD support this concept. In UC it appe-
ars slightly different, since the AUCs of ratios are higher 
than 0.5 and close to 0.7. It may suggest that neutro-
phils are more activated in UC than in CD. Neutrophils 
are among the first cells migrating from the blood to the 
sites of inflammation. The perception of their role in the 
inflammatory process has significantly changed lately. 
The opinion that neutrophils are only cells responding 
to inflammatory mediators has changed after demon-
strating the ability of activated neutrophils to act as 
macrophages [26]. It was observed that the number of 
neutrophils with polarized cell membrane is higher in 
patients with IBD compared to healthy subjects [10,12]. 
What is more, there are data suggesting the role of 
abnormal neutrophil function in the pathogenesis of 
IBD. In patients with CD hydrogen peroxide production 
and phagocytosis were reported to be impaired [5,9]. 
Neutrophil dysfunction observed in CD seems to be rela-
ted to the defect in macrophage response. In vitro and in 
vivo studies on macrophages derived from CD patients 
showed a decrease in proinflammatory cytokine pro-
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